Join us for a CEU-approved webinar series! Evolving Strategies in Genetics and Genomics 2026: Enhancing Colorectal Cancer Care Through Genetics and Clinical Collaboration. April 9, 2026 | 2:00 PM ET

MYRIAD ONCOLOGY FOR GENETIC COUNSELORS

Complementing your expertise with exactly what you need

Receive guideline-driven insights, industry-leading accuracy, and seamless workflow support that complements your care, as and when you need it, so you can help even more patients.

Choose a highly actionable and guideline-driven multigene panel

As a genetic counselor, you rely on accurate insights and clear reporting to guide patients through some of their most important health decisions.

The MyRisk® Hereditary Cancer Test is a multigene panel built for clinical action

  • Analyzes 63 guideline-recommended genes across 11+ cancer types
  • Covers 100% of the genes more strongly recommended by ASCO guidelines1,2
  • Only includes genes cited in national oncology guidelines, helping to avoid the uncertainty associated with non-actionable results1-4
  • Every MyRisk® Test report consolidates critical details — germline findings, family history, personalized risk estimates, and guideline-based medical management recommendations — plus patient-friendly explanations and resources for sharing with family

View the full gene list and medical management recommendations

Turn uncertainty into clarity with Myriad’s advanced gene variant diagnostic tools

The MyRisk Test leverages Myriad’s industry-leading Variant Classification Program to deliver highly accurate variant interpretations and clear results.

  • Industry’s lowest reported rates of variants of uncertain significance (VUS) for key hereditary cancer genes, including BRCA1 (0.3%) and BRCA2 (0.7%)5
  • Definitively classifies 63% of variants labeled VUS by other labs6
  • Most variants are classified through advanced baseline DNA analysis without the need for upfront RNA testing — with 99% analytical sensitivity and specificity7-10
  • Targeted RNA analysis with allele-specific quantification methodology is offered to patients with an eligible VUS, at no additional cost, often without the need for a re-draw11,12

Reveal hidden breast cancer risk and personalize prevention for every patient

The RiskScore® assessment is the first and only breast cancer risk assessment combining genetics, clinical factors (Tyrer-Cuzick), and polygenic risk to uncover what single gene testing can’t. This helps provide unaffected patients meeting criteria with a comprehensive, personalized assessment of their 5-year and remaining lifetime risk of developing breast cancer — supporting more confident, guideline-informed prevention and screening decisions.

RiskScore shows you the whole picture of breast cancer risk:

  • Improved risk stratification: Two times more predictive of breast cancer risk than Tyrer-Cuzick alone13
  • Clinical impact: Over half of patients who test negative for a hereditary cancer syndrome will have a change in medical management due to their family history of cancer and/or their RiskScore.14
  • Inclusive: Validated with outcomes data from >130,000 patients across all ancestries
  • Comprehensive: Includes all 13 breast cancer susceptibility genes more strongly recommended* (BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11, TP53) and less strongly recommended† (ATM, BARD1, CHEK2, RAD51C, RAD51D, NF1) by ASCO guidelines, as well as recommended Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM)2
  • Program-ready: Can be implemented as part of a Breast Cancer Risk Assessment program to help identify more patients eligible for genetic testing and increased risk monitoring in your clinic
56%vs.10%

5X more patients receive a personalized cancer prevention plan using the MyRisk Test with RiskScore compared to genetic testing alone.14

Professional resources that help you reach more patients for genetic testing

Myriad Oncology™ provides customizable resources that help reduce administrative burden and complement your care, as and when it’s needed. Our services are designed to feel like a natural extension of your practice workflow so you can help even more patients, at no extra cost for you or your patients.

Connect with our team

Patient identification made simple

MyGeneHistory® is digital tool that collects a patient's personal and family cancer history, identifies whether patient meets national guidelines for hereditary cancer testing, and shares results instantly and securely with your practice.

x2

Patients who use MyGeneHistory are more than twice as likely to complete genetic testing.15

Download MyGeneHistory overview

Helping ensure affordable access to genetic testing

We offer transparent pricing with personalized cost estimates, financial assistance, and other affordability options, including direct-pay. Our Customer Support Representatives can help patients navigate costs, coverage, and access financial assistance for those who are uninsured, underinsured, or experiencing financial hardship.

$0

The majority of patients face no out-of-pocket costs for the MyRisk Test.16

On-demand patient support

Myriad’s board-certified Genetic Counselors are available for pre- and post-test phone consultations to address patient questions and help explain the testing process and results. This helps patients arrive at your visits with a stronger baseline understanding, allowing you to begin discussions at a more advanced level, freeing up valuable time for complex, time-sensitive cases and critical clinical decision-making. After each session, secure case notes keep you fully informed without adding to your workload.

+134%

In a real-world case study of a clinic utilizing Myriad’s pre-test education in complement to in-clinic genetic counselling, patient access to genetic services increased by 134% over a 20-month period.17

Fast, seamless ordering and reporting

You can place orders and access results directly through the Myriad Portal and major EMR systems, including Epic and OncoEMR, making it easy to share with patients.

≤14 days

MyRisk Test results are typically delivered within 14 days, or 7 days with STAT priority ordering option for people with breast, colorectal, and pancreatic cancer.

View ordering options

Clear, actionable reporting

Our reports help empower you to quickly turn results into action for your patients and their families. Each MyRisk® Test report combines germline findings, family history, personalized risk estimates, and guideline-based management recommendations—plus patient-friendly explanations and resources for family sharing.

100%

All the genes we test for are cited in national oncology guidelines, helping to avoid the uncertainty associated with non-actionable results.1-4

View a sample report

Dedicated support for your team and practice

Myriad Oncology provides expert assistance across your practice. Our Medical Science Liaisons are available to answer technical and clinical questions whenever you need them. In addition, we offer full support for implementing a Breast Cancer Risk Assessment program, with full rollout coordination, staff training, and operational resources.

+31%

A multi-state health system’s hereditary cancer risk assessment program supported by Myriad and CancerIQ involving 86,640 unaffected women over 7 years, resulted in a 25% increase in guideline-supported genetic testing and a 31% increase in guideline-supported breast screening.18

View Health System case study

Myriad Oncology™ as a Partner

Improving outcomes through genetic testing, together

Myriad Oncology™ is committed to advancing hereditary cancer testing through scientific leadership, transparent data sharing, and collaborative research that moves the entire field forward.

Collaboration that drives research and future innovation

Through the Myriad Collaborative Research Registry™ (MCRR), we work alongside clinicians and genetic counselors to expand knowledge and inform tomorrow’s breakthroughs.

With MCRR, you gain access to:

  • One of the largest pan-cancer registries freely available for research
  • De-identified genetic, genomic, and clinical data on more than 1.3 million patients
  • Available to clinicians and researchers for data exploration and research
Sign up for training and access

A commitment to high-quality, equitable genetic testing for everyone

Myriad is dedicated to reducing disparities and ensuring that all patients, regardless of ancestry, geography, or financial circumstance, have access to accurate hereditary cancer risk assessment.

Our commitments include:

  • The first breast cancer risk assessment validated across all ancestries
  • Quarterly contributions to ClinVar, including >20,000 oncology variant classifications in 2023–24
  • Genetic testing access programs for underserved communities, those without financial support, and patients in rural areas
Explore articles, posters and video presentations

Additional resources

Your work guides patients through critical decisions. We’re here to help with clear insights, streamlined workflows, and personalized support whenever you need it.

Request personalized support

References:
  1. Internal product development data on file at Myriad Genetics, Inc. Last updated 2025.
  2. Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615.
  3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. V2.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 27, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Genetic/Familial High-risk Assessment: Colorectal, Endometrial, and Gastric. V1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 27, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.
  5. Mundt E, McGreevy K, Nix P, Cummings S. Myriad’s Multidisciplinary Approach and Consistent Investment in Variant Classification for Clinical Decision Making [White paper]. Myriad Genetics. 2025.
  6. Gradishar W, Johnson K, Brown K, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. Oncologist. 2017;22(7):797-803.
  7. Eggington JM, Bowles KR, Moyes K, et al. A comprehensive laboratory based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet. 2013;86(3):229-237.
  8. Pruss D, Morris B, Hughes E, et al. Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat. 2014;147(1):119-132.
  9. Judkins T, Leclair B, Bowles K, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer. 2015;15(1).
  10. Morris B, Hughes E, Rosenthal E, Gutin A, Bowles KR. Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm. BMC Genetics. 2016;17(1).
  11. Nix P, Mundt E, Manley S, Coffee B, Roa B. Functional RNA Studies Are a Useful Tool in Variant Classification but Must Be Used With Caution: A Case Study of One BRCA2 Variant. JCO Precis Oncol. 2020;4:730-735.
  12. Nix P, Mundt E, Cummings SA, Roa B, Enhancing variant interpretation in hereditary cancer testing with RNA analysis from residual blood samples. J Clin Oncol. 2025;43(16_suppl):e22595.
  13. Mabey B, Hughes E, Kucera M, et al. Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors. Genet Med. 2024;26(7):101128.
  14. Internal data on file at Myriad Genetics, Inc. Based on MyRisk tests reported between September 1, 2021 and February 1, 2023, ordered for unaffected patients by OB/GYN and Primary Care healthcare providers.
  15. Waldman RN, DeFrancesco MS, Feltz JP, et al. Online Screening and Virtual Patient Education for Hereditary Cancer Risk Assessment and Testing. Obstet Gynecol. 2025;145(2):177-185.
  16. Internal data on file at Myriad Genetics, Inc. Based on a review of 12 months of past claim data for major insurance carriers across the US, the majority of patients face no out-of-pocket costs for their MyRisk Test. Last updated 2024.
  17. Based on Myriad Genetics Internal Data. Last updated 2023.
  18. Internal data on file at Myriad Genetics, Inc. Based on data collected between October 26, 2017 and March 21, 2025 from a multi-state health system.

Locations

United States
Europe
Japan